MedTrace Logo

ctDNA-guided Surveillance for Stage III CRC, a Randomized Intervention Trial

NCT04084249 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 359

Last updated 2026-04-29

No results posted yet for this study

Summary

IMPROVE-IT2 is a randomized multicenter trial comparing the outcomes of ctDNA guided post-operative surveillance and standard-of-care CT-scan surveillance. The hypothesis of this study is that ctDNA guided post-operative surveillance combining ctDNA and radiological assessments could result in earlier detection of recurrent disease and identify more patients eligible for curative treatment.

Conditions

Interventions

DIAGNOSTIC_TEST

ctDNA-analysis

Minimally-invasive blood-based analysis of circulating tumor DNA (ctDNA).

OTHER

Intensified Follow-up Schedule

PET/CT-scans every 3. month

Sponsors & Collaborators

  • University of Aarhus

    collaborator OTHER

  • Claus Lindbjerg Andersen

    lead OTHER

Principal Investigators

  • Claus L Andersen, PhD · Department of Molecular Medicin, Aarhus University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-01
Primary Completion
2028-06-30
Completion
2028-06-30

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04084249 on ClinicalTrials.gov